Here’s a sentence I didn’t expect to write today: a cancer drug is being tested in ALS patients. Trethera Corporation just announced an FDA Expanded Access study of TRE-515 — their first-in-class deoxycytidine kinase (dCK) inhibitor — in up to six patients with advanced ALS, in collaboration with Massachusetts General Hospital.
If you’re thinking “wait, what does a kinase involved in DNA replication have to do with motor neuron disease,” you’re asking the right question. The answer lies in inflammation. dCK isn’t just a cancer target — it sits at the intersection of nucleotide metabolism and inflammatory signaling. There’s emerging evidence that inflammation plays a significant role in ALS pathophysiology, and Trethera is betting that modulating that pathway with TRE-515 could produce signals of activity in a neuroimmune setting.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
This is a bold move, but it’s not a random one. TRE-515 has been accumulating regulatory validation across its original oncology and autoimmune indications. The company completed a Phase 1 dose-escalation trial in solid tumors. They picked up FDA Fast Track designation for prostate cancer. They’ve got orphan drug designation for both cancer and autoimmune diseases. The drug has been in human testing — they know its safety profile.
The ALS study is exploratory — six patients, expanded access, looking for early signals. This isn’t a pivotal trial. It’s a hypothesis test. But it’s a hypothesis test at Mass General, which lends real scientific credibility. And for ALS patients with advanced disease, expanded access programs represent one of the few paths to trying something new.
What makes this strategically interesting is the optionality it creates. If TRE-515 shows even a hint of activity in neuroinflammation, Trethera goes from being an oncology company with an autoimmune angle to a platform company sitting on a multi-indication asset that spans cancer, autoimmune disease, and neurodegeneration. That’s a very different valuation conversation. Six patients won’t prove anything definitively — but they might open a door nobody expected.
